Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14981499150015011502150315041505150615071508...15771578»
  • ||||||||||  Review, Journal:  Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. (Pubmed Central) -  Jul 26, 2017   
    Finally, we will look forward at the future therapies that are ever evolving for management of GIST. Taken together, the scientific advances in understanding the molecular basis of GIST validates the importance of knowing and understanding the mutations that are present in any one patient.
  • ||||||||||  Erivedge (vismodegib) / Roche
    Trial primary completion date, IO biomarker, Metastases:  Vismodegib in Treating Patients With Advanced Chondrosarcomas (clinicaltrials.gov) -  Jul 26, 2017   
    P2,  N=45, Active, not recruiting, 
    Trial primary completion date: Oct 2017 --> Jan 2018 Trial primary completion date: Jun 2016 --> Jun 2018
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
    Journal:  Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. (Pubmed Central) -  Jul 23, 2017   
    Trial primary completion date: Dec 2017 --> Apr 2018 Although occasional responses to immunotherapy have been reported for sarcomas, this case report demonstrates that angiosarcoma can express PD-L1 and have a sustained response to PD-1 directed therapy.
  • ||||||||||  Journal:  Ewing sarcoma family of tumors in children younger than 10 years of age. (Pubmed Central) -  Jul 23, 2017   
    It will be important to relate the drug levels in mice at 50 mg/kg to those in humans at the recommended phase 2 dose. Patients younger than 10 years of age with ESFT may have a better OS than older patients, but further study of a homogeneously treated larger cohort is needed.
  • ||||||||||  Enrollment closed:  Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions (clinicaltrials.gov) -  Jul 21, 2017   
    P=N/A,  N=29, Active, not recruiting, 
    Patients with pathologic fracture suffer worse functional outcomes but no decrease in overall survival. Enrolling by invitation --> Active, not recruiting
  • ||||||||||  Enrollment change, Trial withdrawal:  Adoptive Therapy Using Antigen-Specific CD4 T-Cells (clinicaltrials.gov) -  Jul 21, 2017   
    P1,  N=0, Withdrawn, 
    N=42 --> 84 N=12 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  docetaxel / Generic mfg., gemcitabine / Generic mfg.
    Journal:  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy. (Pubmed Central) -  Jul 19, 2017   
    For metastatic YWHAE-rearranged HG-ESS, prolonged disease control following diagnosis was seen, with notable responses to anthracycline-based therapy. This emphasizes the need for appropriate molecular testing of uterine mesenchymal malignancies and suggests that chemotherapy is an effective treatment option for metastatic YWHAE-rearranged HG-ESS.
  • ||||||||||  Journal:  Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. (Pubmed Central) -  Jul 19, 2017   
    This emphasizes the need for appropriate molecular testing of uterine mesenchymal malignancies and suggests that chemotherapy is an effective treatment option for metastatic YWHAE-rearranged HG-ESS. This study confirms the previously reported surgical pathological findings for endometrioid cancers but in addition, using a large database of papillary serous, clear cell and carcinosarcoma, surgical pathological findings substantiate the categorization of poor histotypes for these cancers.
  • ||||||||||  Trial initiation date, Trial primary completion date:  Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia (clinicaltrials.gov) -  Jul 19, 2017   
    P1,  N=40, Not yet recruiting, 
    A limitation of this systematic review is that lesions amenable to subsequent resection or tumors inherently more sensitive to adjuvants would exaggerate a therapeutic effect of these interventions when studied in a retrospective fashion. Initiation date: Jun 2017 --> Sep 2017 | Trial primary completion date: Jun 2018 --> Sep 2018
  • ||||||||||  Enrollment closed, Trial primary completion date, HEOR:  Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors (clinicaltrials.gov) -  Jul 17, 2017   
    P=N/A,  N=455, Active, not recruiting, 
    Completed --> Terminated; The study was targeted to accrue 130 patients, but closed early for futility. Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018